Hydroxyamide Compounds for Metabolic Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes and insulin resistance syndrome are inadequate, with existing drugs often causing side effects and failing to effectively address the primary defects of insulin resistance and islet failure, while there is a lack of safe and effective treatments for fatty liver disease.
Innovation Solution
Development of specific hydroxyamide-substituted compounds and their pharmaceutically acceptable salts, which are administered to treat insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis, or arteriosclerosis, demonstrated to be effective in animal models of human diabetes and insulin resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing drugs for diabetes and insulin resistance are used, then some therapeutic effect is achieved, but side effects occur and primary defects are not effectively addressed
Solution Approach 1:
The patent employs parameter changes by developing a new class of compounds with modified chemical structures (Formula I with specific substituents R1-R4, groups A, B, and linkers L1-L3) to achieve improved therapeutic profiles. The compounds are designed with specific molecular weight ranges (350-700 Da) and structural parameters to optimize both efficacy and safety, resolving the contradiction between effectiveness and side effects through systematic modification of chemical parameters
Solution Approach 2:
The invention utilizes composite molecular structures combining multiple functional groups (amide, hydroxyamide, carboxylic acid, ester, ketone, aldehyde) within a single compound framework. This composite approach allows different parts of the molecule to address different aspects of insulin resistance and metabolic dysfunction simultaneously, improving overall effectiveness while maintaining safety through balanced pharmacological activity
2Reliability
If insulin releasers are used to stimulate insulin release, then blood glucose control is improved, but risk of hypoglycemia increases
Solution Approach 1:
The compounds act as intermediaries that improve insulin sensitivity in peripheral tissues rather than directly stimulating insulin secretion. By mediating the insulin signal transduction pathway through PPAR-gamma activation and improved cellular responsiveness, the compounds achieve blood glucose control without the hypoglycemia risk associated with direct insulin releasers
3Reliability
If insulin sensitizers like thiazolidinediones are used to improve peripheral responsiveness to insulin, then insulin sensitivity is improved, but weight gain and edema occur
Solution Approach 1:
The compounds exhibit local quality by selectively improving insulin sensitivity in specific tissues (muscle, adipose, liver) through targeted PPAR-gamma activation, while the molecular design parameters (specific substituents, molecular weight range) are optimized to minimize systemic side effects like weight gain and edema that occur with conventional thiazolidinediones
4Reliability
If biguanides like metformin are used to attenuate hepatic gluconeogenesis, then fasting glucose is reduced, but lactic acidosis risk increases
Solution Approach 1:
The patent replaces the mechanical/systemic approach of biguanides (which broadly inhibit mitochondrial respiration and gluconeogenesis) with a more selective molecular mechanism involving PPAR-gamma activation and improved insulin signaling. This substitution of the underlying mechanism achieves hepatic gluconeogenesis suppression through insulin-sensitive pathways rather than direct mitochondrial inhibition, reducing lactic acidosis risk
5Reliability
If multiple daily insulin injections are administered to type I diabetes patients, then blood glucose control is maintained, but treatment complexity and hypoglycemia risk increase
Solution Approach 1:
The compounds demonstrate multi-functionality by addressing multiple aspects of metabolic dysfunction simultaneously (insulin sensitivity improvement, hepatic gluconeogenesis suppression, lipid metabolism regulation, anti-inflammatory effects) through a single oral agent, thereby simplifying treatment regimens while maintaining effective blood glucose control
Data Source
AI summary
Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. wherein n is 1 or 2; m is 0, 1, 2, 3, 4 or 5; q is 0 or 1; t is 0 or 1; R1 is alkyl having from 1 to 3 carbon atoms; R2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; R3 is hydrogen or —(CH2)gOH wherein g is 0, 1 or 2; R4 is hydrogen, methyl or ethyl; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; or a pharmaceutically acceptable salt of the compound.